Kamada (KMDA) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kamada Ltd., a global biopharmaceutical company, is set to announce its financial results for the third quarter and nine months ending September 30, 2024, on November 13, 2024. Known for its expertise in specialty plasma-derived products, Kamada continues to expand its product portfolio and market presence across over 30 countries. Investors are keenly watching Kamada’s progress, especially with its ongoing Phase 3 trial for an inhaled treatment for AAT deficiency.
For further insights into KMDA stock, check out TipRanks’ Stock Analysis page.